What next for newly diagnosed glioblastoma?

Future Oncology

Volumn 11, Issue 24, 2015, Pages 3273-3283

  Domingo Musibay, Evidio ^a   Galanis, Evanthia ^a  

^a MAYO CLINIC   (United States)

Author keywords

bevacizumab; glioblastoma; newly diagnosed; novo TTF; radiation therapy; temozolomide

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ANGIOGENESIS INHIBITOR; BASILIXIMAB; BEVACIZUMAB; CARMUSTINE; CRIZOTINIB; DENDRITIC CELL VACCINE; GRANISETRON; INIPARIB; INTERFERON; IPILIMUMAB; LAPATINIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; NIVOLUMAB; OLAPARIB; ONCOLYTIC VIRUS; PAZOPANIB; PEMBROLIZUMAB; PEPTIDE VACCINE; RINDOPEPIMUT; SITIMAGENE CERADENOVEC; TEMOZOLOMIDE; VELIPARIB; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL THERAPY; CHEMORADIOTHERAPY; DENDRITIC CELL; DNA METHYLATION; DRUG DOSE INTENSIFICATION; EXPERIMENTAL THERAPY; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; PROTON THERAPY; RADIATION DOSE; REGULATORY T LYMPHOCYTE; REVIEW; STEREOTACTIC RADIOSURGERY; SUPPRESSOR CELL; AGE; BRAIN NEOPLASMS; CLINICAL DECISION MAKING; DISEASE MANAGEMENT; GENE THERAPY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PROCEDURES;

AGE FACTORS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL DECISION-MAKING; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; GENETIC THERAPY; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; ONCOLYTIC VIROTHERAPY; STANDARD OF CARE;

EID: 84948949955     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.258     Document Type: Review

References (55)

1. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009).
2. Galanis E, Buckner JC, Dinapoli RP et al. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J. Neurosurg. 89(3), 425-430 (1998).
3. Kozak KR, Moody JS. Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. Neuro Oncol. 11(6), 833-841 (2009).
4. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114(2), 97-109 (2007).
5. Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303(23), 1323-1329 (1980).
6. Souhami L, Seiferheld W, Brachman D et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int. J. Radiat. Oncol. Biol. Phys. 60(3), 853-860 (2004).
7. Fitzek MM, Thornton AF, Rabinov JD et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a Phase II prospective trial. J. Neurosurg. 91(2), 251-260 (1999).
8. Stupp R, Mason WP, Van Den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005).
9. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359(9311), 1011-1018 (2002).
10. Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr. Mol. Pharmacol. 5(1), 102-114 (2012).
11. D'atri S, Tentori L, Lacal PM et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol. Pharmacol. 54(2), 334-341 (1998).
12. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005).
13. Wick W, Weller M, Van Den Bent M et al. MGMT testing - the challenges for biomarker-based glioma treatment. Nat. Rev. Neurol. 10(7), 372-385 (2014).
14. Gilbert MR, Wang M, Aldape KD et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized Phase III clinical trial. J. Clin. Oncol. 31(32), 4085-4091 (2013).
15. De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, Van Herpen CM. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. Crit. Rev. Oncol. Hematol. 85(3), 373-382 (2013).
16. Chinot OL, Wick W, Mason W et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370(8), 709-722 (2014).
17. Gilbert MR, Dignam JJ, Armstrong TS et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370(8), 699-708 (2014).
18. Stupp R, Hegi ME, Gorlia T et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, Phase 3 trial. Lancet Oncol. 15(10), 1100-1108 (2014).
19. Nabors LB, Fink KL, Mikkelsen T et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized Phase II CORE study. Neuro Oncol. 17(5), 708-717 (2015).
20. Stupp R, Taillibert S, Kanner A et al. Tumor treating fields (TTFields): a novel treatment modality added to standard chemo-and radiotherapy in newly diagnosed glioblastoma-first report of the full dataset of the EF14 randomized Phase III trial. J. Clin. Oncol. 33(Suppl. 15), Abstract 2000 (2015).
21. Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897), 1807-1812 (2008).
22. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216), 1061-1068 (2008).
23. Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3), 157-173 (2006).
24. Brennan CW, Verhaak RG, McKenna A et al. The somatic genomic landscape of glioblastoma. Cell 155(2), 462-477 (2013).
25. Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1), 98-110 (2010).
26. Sandmann T, Bourgon R, Garcia J et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J. Clin. Oncol. 33(25), 2735-2744 (2015).
27. Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J. Clin. Oncol. 22(9), 1583-1588 (2004).
28. Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, Phase 3 trial. Lancet Oncol. 13(9), 916-926 (2012).
29. Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, Phase 3 trial. Lancet Oncol. 13(7), 707-715 (2012).
30. Clinical; Trials Database: NCT00482677. https://clinicaltrials.gov
31. Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Ann. NY Acad. Sci. 1291, 86-95 (2013).
32. Kleinberg LR, Supko JG, Mikkelsen T et al. Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data. J. Clin. Oncol. 31(Suppl.), Abstract 2065 (2013).
33. Clarke MJ, Mulligan EA, Grogan PT et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol. Cancer Ther. 8(2), 407-414 (2009).
34. Quinn JA, Jiang SX, Reardon DA et al. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J. Clin. Oncol. 27(8), 1262-1267 (2009).
35. Adair JE, Johnston SK, Mrugala MM et al. Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J. Clin. Invest. 124(9), 4082-4092 (2014).
36. Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 5(2), 79-88 (2003).
37. Mcgirt MJ, Than KD, Weingart JD et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J. Neurosurg. 110(3), 583-588 (2009).
38. Salvati M, D'elia A, Frati A, Brogna C, Santoro A, Delfini R. Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis. J. Neurosurg. Sci. 55(1), 1-6 (2011).
39. Miglierini P, Bouchekoua M, Rousseau B, Hieu PD, Malhaire JP, Pradier O. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity. Clin. Neurol. Neurosurg. 114(9), 1222-1225 (2012).
40. Noel G, Schott R, Froelich S et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int. J. Radiat. Oncol. Biol. Phys. 82(2), 749-755 (2012).
41. Groves MD, Puduvalli VK, Gilbert MR et al. Two Phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br. J. Cancer 101(4), 615-620 (2009).
42. Yung WK, Prados M, Levin VA et al. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a Phase I/II study. J. Clin. Oncol. 9(11), 1945-1949 (1991).
43. Motomura K, Natsume A, Kishida Y et al. Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer 117(8), 1721-1730 (2011).
44. ClinicalTrials database: NCT00045968. https://clinicaltrials.gov
45. Hdeib A, Sloan AE. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme. CNS Oncol. 4(2), 63-69 (2015).
46. Mitchell DA, Batich KA, Gunn MD et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519(7543), 366-369 (2015).
47. Bloch O, Raizer JJ, Lim M. Newly diagnosed glioblastoma patients treated with an autologous heat shock protein peptide vaccine: PD-L1 expression and response to therapy. J. Clin. Oncol. 33(15s), Abstract 2011 (2015).
48. Schuster J, Lai RK, Recht LD et al. A Phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 17(6), 854-861 (2015).
49. Reardon DA, Schuster JM, Tran DD et al. 107 ReACT: overall survival from a randomized Phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. Neurosurgery 62(Suppl. 1), 198-199 (2015).
50. Brown CE, Badie B, Barish ME et al. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res. 21(18), 4062-4072 (2015).
51. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14(8), 559-567 (2014).
52. Lang FF. NT-18 Phase I clinical trial of oncolytic virus delta-24-RGD (DNX-2401) with biological endpoints: implications for viro-immunotherapy. Neuro Oncol. 16(Suppl. 5), v162 (2014).
53. Rainov NG. A Phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11(17), 2389-2401 (2000).
54. Westphal M, Yla-Herttuala S, Martin J et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, Phase 3 trial. Lancet Oncol. 14(9), 823-833 (2013).
55. Galanis E, Wu W, Cloughesy T et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 13(5), e196-e204 (2012).